PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page

First FDA Approved Targeted RNA-based Therapy

by PEPID Newsroom | Aug 16, 2018 | Alerts

The U.S. FDA approved the first of its kind targeted RNA-based therapy Onpattro (patisiran) to treat peripheral nerve disease (polyneuropathy) caused from hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA approved treatment...

Recent Posts

  • The Summer Injury Spike: Common ER Visits and How to Prevent Them
  • Men’s Health Month – Closing Gaps in Prevention and Early Detection
  • Beyond the Beach – Occupational Skin Cancer Risks in Outdoor Workers
  • Tackling Antimicrobial Resistance: How to fight back against the rise in tough cases
  • The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved